Rosinidin Inhibits NF-κB/ Nrf2/caspase-3 Expression and Restores Neurotransmitter Levels in Rotenone-activated Parkinson's Disease

Overview

Journal Saudi J Biol Sci

Specialty Biology

Date 2023 May 15

PMID 37187936

Authors

Amira M Alghamdi

Fahad A Al-Abbasi

Shareefa A Alghamdi

Farhat Fatima

Sami I Alzarea

Imran Kazmi

Affiliations

Soon will be listed here.

Abstract

Objectives: The examination was sighted to study the preventive effects of rosinidin against rotenone-activated Parkinson's disease in rats.

Methods: Animals were randamoized into five groups: I-saline, II-rotenone (0.5 mg/kg/b.wt.), III- IV-10 and 20 mg/kg rosinidin after rotenone and V-20 mg/kg rosinidin per se for 28 days and were assigned for behavioral analysis., Biochemical parameters i.e. lipid peroxidation, endogenous antioxidants, nitrite level, neurotransmitter levels, proinflammatory biomarkers such as interleukin- 6 (IL-6), tumor necrosis factor-α, IL-1β, nuclear factor kappa B, nuclear factor erythroid 2-related factor 2, and caspase-3 were assessed on the 29th day of the research.

Results: Rosinidin augmented the effectiveness of rotenone on akinesia, catalepsy, forced-swim test, rotarod, and open-field test. Biochemical findings indicated that treatment of rosinidin showed restoring neuroinflammatory cytokines, antioxidants, and neurotransmitter levels in rotenone-injected rats.

Conclusion: As a result of rosinidin treatment, the brain was protected from oxidative stress-induced neuronal damage and inhibited neuroinflammatory cytokines.

Citing Articles

In vivo and in silico study of europinidin against streptozotocin-isoproterenol-induced myocardial damage via alteration of hs-CRP/CPK-MB/Caspase-3/Bcl-2 pathways.

Alharbi K, Afzal M, Al-Abbasi F, Moglad E, Al-Qahtani S, Almalki N Sci Rep. 2025; 15(1):3076.

PMID: 39856142 PMC: 11761472. DOI: 10.1038/s41598-024-83900-8.

A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.

Frent O, Stefan L, Morgovan C, Duteanu N, Dejeu I, Marian E Int J Mol Sci. 2024; 25(22).

PMID: 39596162 PMC: 11594109. DOI: 10.3390/ijms252212091.

6-Shogaol Abrogates Parkinson's Disease in Rotenone-Induced Rodents: Based on In Silico Study and Inhibiting TNF-α/NF-κB/IL-1β/MAO-B.

Rafeeq M, Al-Abbasi F, Afzal M, Moglad E, Al-Qahtani S, Alzrea S Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458989 PMC: 11510247. DOI: 10.3390/ph17101348.

Research on the mechanism of Ursolic acid for treating Parkinson's disease by network pharmacology and experimental verification.

Sun A, Li Y, Miao Y, Wang H, Zhang L Heliyon. 2024; 10(14):e34113.

PMID: 39108896 PMC: 11301175. DOI: 10.1016/j.heliyon.2024.e34113.

References

Asakawa T, Fang H, Sugiyama K, Nozaki T, Hong Z, Yang Y . Animal behavioral assessments in current research of Parkinson's disease. Neurosci Biobehav Rev. 2016; 65:63-94. DOI: 10.1016/j.neubiorev.2016.03.016. View

Truong D, Bhidayasiri R, Wolters E . Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci. 2007; 266(1-2):216-28. DOI: 10.1016/j.jns.2007.08.015. View

Kuniishi H, Ichisaka S, Yamamoto M, Ikubo N, Matsuda S, Futora E . Early deprivation increases high-leaning behavior, a novel anxiety-like behavior, in the open field test in rats. Neurosci Res. 2017; 123:27-35. DOI: 10.1016/j.neures.2017.04.012. View

Anandhan A, Essa M, Manivasagam T . Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease. Neurotox Res. 2012; 23(2):166-73. DOI: 10.1007/s12640-012-9332-9. View

Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J . Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. Crit Rev Toxicol. 2012; 42(7):613-32. DOI: 10.3109/10408444.2012.680431. View

Zahedi-Amiri Z, Taravati A, Beigom Hejazian L . Protective Effect of Rosa damascena Against Aluminum Chloride-Induced Oxidative Stress. Biol Trace Elem Res. 2018; 187(1):120-127. DOI: 10.1007/s12011-018-1348-4. View

Weydert C, Cullen J . Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc. 2010; 5(1):51-66. PMC: 2830880. DOI: 10.1038/nprot.2009.197. View

Monti B, Gatta V, Piretti F, Raffaelli S, Virgili M, Contestabile A . Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res. 2009; 17(2):130-41. DOI: 10.1007/s12640-009-9090-5. View

Alharthy K, Althurwi H, Albaqami F, Altharawi A, Alzarea S, Al-Abbasi F . Barbigerone Potentially Alleviates Rotenone-Activated Parkinson's Disease in a Rodent Model by Reducing Oxidative Stress and Neuroinflammatory Cytokines. ACS Omega. 2023; 8(5):4608-4615. PMC: 9910078. DOI: 10.1021/acsomega.2c05837. View

10.

Eskow Jaunarajs K, Angoa-Perez M, Kuhn D, Bishop C . Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev. 2010; 35(3):556-64. PMC: 2987522. DOI: 10.1016/j.neubiorev.2010.06.007. View

11.

Parkhe A, Parekh P, Nalla L, Sharma N, Sharma M, Gadepalli A . Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson's disease. Neurosci Lett. 2019; 716:134652. DOI: 10.1016/j.neulet.2019.134652. View

12.

Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J . Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011; 32(1):7-24. View

13.

Malar D, Prasanth M, Brimson J, Sharika R, Sivamaruthi B, Chaiyasut C . Neuroprotective Properties of Green Tea () in Parkinson's Disease: A Review. Molecules. 2020; 25(17). PMC: 7504552. DOI: 10.3390/molecules25173926. View

14.

Alikatte K, Palle S, Rajendra Kumar J, Pathakala N . Fisetin Improved Rotenone-Induced Behavioral Deficits, Oxidative Changes, and Mitochondrial Dysfunctions in Rat Model of Parkinson's Disease. J Diet Suppl. 2020; 18(1):57-71. DOI: 10.1080/19390211.2019.1710646. View

15.

Hirsch E, Hunot S . Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009; 8(4):382-97. DOI: 10.1016/S1474-4422(09)70062-6. View

16.

Gilani S, Bin-Jumah M, Al-Abbasi F, Nadeem M, Alzarea S, Ahmed M . Rosinidin Protects against Cisplatin-Induced Nephrotoxicity via Subsiding Proinflammatory and Oxidative Stress Biomarkers in Rats. Int J Environ Res Public Health. 2022; 19(15). PMC: 9368304. DOI: 10.3390/ijerph19159719. View

17.

Mosley R, Benner E, Kadiu I, Thomas M, Boska M, Hasan K . Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res. 2007; 6(5):261-281. PMC: 1831679. DOI: 10.1016/j.cnr.2006.09.006. View

18.

Ball N, Teo W, Chandra S, Chapman J . Parkinson's Disease and the Environment. Front Neurol. 2019; 10:218. PMC: 6433887. DOI: 10.3389/fneur.2019.00218. View

19.

Chonpathompikunlert P, Boonruamkaew P, Sukketsiri W, Hutamekalin P, Sroyraya M . The antioxidant and neurochemical activity of Apium graveolens L. and its ameliorative effect on MPTP-induced Parkinson-like symptoms in mice. BMC Complement Altern Med. 2018; 18(1):103. PMC: 5859653. DOI: 10.1186/s12906-018-2166-0. View

20.

Zhang Q, Heng Y, Mou Z, Huang J, Yuan Y, Chen N . Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease. Acta Pharmacol Sin. 2017; 38(10):1317-1328. PMC: 5630672. DOI: 10.1038/aps.2017.49. View